• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Home
  • Insights & Articles
    • The Clinical Landscape: Strategic Insights into Retinal Care
      • The Modern Clinical Retina Landscape: A Strategic Overview
      • Surgical Approaches to Retinal Detachment: A Comparative Analysis
      • Gene Therapy in Retina: A Commercial and Clinical Appraisal
      • Evolving Treatment Paradigms for Diabetic Macular Edema
      • Analysis of the Anti-VEGF Market: From Revolution to Refinement
      • A Patient’s Guide to Understanding Age-Related Macular Degeneration (AMD)
    • The Business of Retina: Mastering Operations and Financial Health
      • Anatomy of a Retina Practice: A Strategic Guide to Financial Health and Operations
      • The Impact of Private Equity: Reshaping the Business of Retina
      • The Complete 2025 Guide to Ophthalmic J-Codes & Reimbursement
      • The Buy-and-Bill Model: A High-Risk, High-Reward Strategy
      • Staffing for Success: Key Roles in a High-Volume Retina Practice
      • Key Technology Investments for an Efficient Retina Clinic
      • Decoding CMS Reimbursement: A Guide to J-Codes and Revenue Cycle Management
    • The Innovation Pipeline: Shaping the Future of Retinal Care
      • Beyond the Needle: The Future of Drug Delivery in Retina
      • Heads-Up vs. Traditional: A Comparison of Surgical Visualization Platforms
      • How AI is Changing the Game in Retinal Disease Screening
      • The Rise of At-Home Monitoring for AMD
    • The Professional Ecosystem: Building a Career in Retina
      • A Day in the Life of a Retina Specialist: A Day of Preserving Sight
      • Industry vs. Academia: Choosing Your Career Path in Retina
      • The Role of Key Opinion Leaders (KOLs) in Retina
      • Maximizing Your ASRS Experience: A Fellow’s Guide
      • Navigating the Retina World: A Guide to Key Societies, Conferences, and Career Paths
  • Services
    • Search Engine Optimization (SEO) & Reputation Management
    • Content Marketing & Optometrist Network Development
    • Specialized Recruitment & Staffing Support
    • Professional Branding & Key Opinion Leader (KOL) Development
    • On-Demand Patient Education & Marketing Materials
    • Market Intelligence & M&A Consulting
  • Contact Us
    • Events
    • Subscribe
    • Submissions
Retina Consultant

Retina Consultant

Visionary News & Insightful Strategy

Retina Roundup Advertisement

FDA approves Zeiss MEL 90 excimer laser

January 13, 2025 by Retina News Feed Leave a Comment

Click here to view the original post by Ophthalmology Times.

In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina & ophthalmology landscape, Full credit belongs to the original authors and publication. 

By clicking the link above, you will be leaving our site to view an article from its original source.


Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.

Please enable JavaScript in your browser to complete this form.
Loading


The FDA has granted its approval to the excimer laser MEL 90 from Zeiss Meditech for all 3 major indications: myopia, hyperopia, and mixed astigmatism. The laser fully integrates into the Corneal Refractive Workflow from Zeiss as a complement to Visumax 800 and SMILE pro software to streamline surgical correction with positive outcomes. The MEL 90 is currently available in the US.

“ZEISS continues to break new ground as a leader in the LVC market, reflecting our ongoing commitment to and support of U.S. surgeons and patients with the latest refractive innovation that helps set practices apart and provides more options to more patients,” Andrew Chang, Head of Global Sales for ZEISS Medical Technology, said in a press release. “With the availability of the ZEISS MEL 90 in the U.S. market, surgeons can now offer an integrated workflow of refractive technology to help reach new patients and provide excellent outcomes for them.”

The MEL 90 excimer laser boasts of a single ablation profile for a wide range of sphero-cylindrical (SCA) corrections, coined by the company as Triple-A (advanced ablation algorithm). Zeiss claims that Triple-A offers a high degree of accuracy, reproducibility, and predictability in addition to tissue-saving ablation. The fast ablation speed is also of note: When performing LASIK for myopia at 500 Hz, Zeiss’s MEL 90 excimer laser can ablate 1 diopter in as little as 1.3 seconds (optical zone, 6 mm). Additionally, the laser technology features an active eye tracker for improved response time, a high level of treatment safety, and stable results.

“The FDA approval of the ZEISS MEL 90 excimer laser is a game changer for refractive surgery in the U.S. This advanced technology, with its Triple-A ablation algorithm and fast ablation speed, sets a new benchmark for precision, safety, and efficiency. I am particularly impressed by the system’s ability to simplify treatment planning while delivering highly predictable and tissue-conserving results. The integration of the ZEISS MEL 90 with the ZEISS VISUMAX 800 femtosecond laser opens new doors for streamlined workflows and optimal patient outcomes. This approval marks an exciting chapter for surgeons and patients alike,” John Doane, MD, a refractive surgeon at Discover Vision Centers in Kansas City, Missouri, said in a press release.

While the excimer laser comes pre-installed functions that achieve excellent treatment results for standard, higher, and lower levels of ametropia and astigmatism, it is also customizable. Custom configurations may be adjusted to the surgeon or the team’s preferences; the touch screen can be positioned to fit the surgical space, a second touch screen can be added to complement the treatment routine, and additional connection options (HD video port, network printer connection, and PDF export) allow surgeons to configure the device to their practice.

“The increasing global adoption of laser vision correction reflects the advancements and positive impact the technology continues to have on the quality of life for patients,” Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology, said in a press release. “With the integration of the ZEISS MEL 90, surgeons can confidently care for their patients with greater workflow efficiency and performance with enhanced outcomes.”

Reference:
  1. ZEISS MEL 90 excimer laser receives U.S. FDA approval; completes Corneal Refractive Workflow. PR News Wire. Press release. Published January 13, 2025. Accessed January 13, 2025. https://www.prnewswire.com/news-releases/zeiss-mel-90-excimer-laser-receives-us-fda-approval-completes-corneal-refractive-workflow-302349058.html

Filed Under: Ophthalmology Times

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

More to See

Week in Review: Patient Education Chatbot, Compensation Disparities Among Ophthalmology Faculty

April 3, 2026 By AAO News Feed

After a Failed Penetrating Keratoplasty, Either DSAEK or DMEK Could Be an Option

April 2, 2026 By AAO News Feed

Safety and Biodistribution of Topical Laquinimod, an Immunomodulator Targeting Aryl Hydrocarbon Receptor: The LION Study

April 2, 2026 By Ophthalmology Science

First-in-Human Clinical Evaluation of a Novel Non-Surgical Suprachoroidal Delivery Approach for Triamcinolone in Diabetic Macular Edema

April 2, 2026 By Ophthalmology Science

Who Gets Panretinal Photocoagulation? National Patterns in Proliferative Diabetic Retinopathy Treatment

April 2, 2026 By Ophthalmology Science

Weekly Journal Update — April 1, 2026

April 1, 2026 By AAO News Feed

A VR-Based Visual Field Test Has Utility in Children With Neuro-ophthalmic Disease

April 1, 2026 By AAO News Feed

Zero warm ischemia time in whole-eye transplantation through retrograde extracorporeal perfusion

April 1, 2026 By Ophthalmology Science

Some Patients With Punctate Inner Choroidopathy Can Experience Visual Impairment

March 31, 2026 By AAO News Feed

Patterns of X-linked Retinitis Pigmentosa Genetic Testing in England and Implications for Service Provision

March 31, 2026 By Ophthalmology Science

Footer

A RETINA-SPECIFIC ORGANIZATION

It’s clearly an advantage to work with a consulting group that’s focused on your industry. The team at Retina Consultant has over 50 years of retina-specific experience in healthcare business, practice management, marketing & operations.

We’ve got our eyes on working with the best retina groups and vendors in the industry.

See the best;  get in touch.

Recent News Posts

  • Tenecteplase Shows No Benefit Over Aspirin for Acute Central Retinal Artery Occlusion
  • Week in Review: Patient Education Chatbot, Compensation Disparities Among Ophthalmology Faculty
  • After a Failed Penetrating Keratoplasty, Either DSAEK or DMEK Could Be an Option
  • Safety and Biodistribution of Topical Laquinimod, an Immunomodulator Targeting Aryl Hydrocarbon Receptor: The LION Study
  • First-in-Human Clinical Evaluation of a Novel Non-Surgical Suprachoroidal Delivery Approach for Triamcinolone in Diabetic Macular Edema

Search

Retina Consultant
Copyright © 2026